Retatrutide: The Triple Agonist
How a single peptide targeting three receptors became the most effective obesity drug in clinical trials
The Next Frontier in Obesity Medicine
In 2023, a New England Journal of Medicine trial reset expectations for obesity pharmacology: a once-weekly peptide drove approximately 24.2% mean body-weight loss in 48 weeks. That peptide was retatrutide (LY3437943), a single molecule built to activate three metabolic hormone receptors at once.
Developed by Eli Lilly, retatrutide marks the next step after semaglutide and tirzepatide: a triple agonist that combines GIP, GLP-1, and glucagon signaling in one injectable therapy. This unit explains why that third receptor changed the ceiling.
retatrutide at a glance
what this course covers
why a third receptor
more than 1 billion people worldwide live with obesity, including roughly 890 million adults (world obesity federation, 2024). the disease burden runs through type 2 diabetes, cardiovascular disease, fatty liver disease, osteoarthritis, and several cancers.
where the field actually was before retatrutide
what drugs already did well
- STEP 1 (semaglutide 2.4 mg): mean weight loss ~15% at 68 weeks (Wilding 2021).
- SURMOUNT-1 (tirzepatide 15 mg): mean weight loss ~22.5% at 72 weeks (Jastreboff 2022).
- glycemic control: reliable HbA1c reduction across the GLP-1 class.
- cardiovascular: SELECT showed semaglutide cut MACE risk in established disease (Lincoff 2023).
what the field still left on the table
- surgical-tier weight loss was still mostly out of reach with mono and dual agonists.
- energy expenditure was not directly engaged by GLP-1 or GIP alone -- only the "energy in" side.
- hepatic fat reduction was modest unless weight loss itself drove it.
- response variability: a meaningful tail of patients lost less than 5% on existing agonists.
eli lilly's bet was straightforward: if a second receptor (GIP) moved the field past 20%, a carefully tuned third receptor (glucagon) might move it again without breaking glycemic control. the open question was whether glucagon agonism, historically avoided in diabetes drugs because it raises blood sugar, could be balanced by simultaneous GLP-1 agonism on the same molecule (Coskun et al. 2022).
from mono to triple
the incretin drug revolution happened in three waves, each adding a new receptor target and raising the mean weight-loss ceiling.
-
1
wave 1 -- GLP-1 mono-agonists
liraglutide (2010) and then semaglutide (2017) proved that GLP-1 receptor activation alone could suppress appetite, slow gastric emptying, and improve glucose control. STEP 1 put mean weight loss at ~15% with semaglutide 2.4 mg over 68 weeks (Wilding 2021).
-
2
wave 2 -- GIP/GLP-1 dual agonists
tirzepatide added GIP receptor agonism on top of GLP-1 in a single 39-residue peptide. SURMOUNT-1 pushed mean weight loss to ~22.5% at 72 weeks at the 15 mg dose (Jastreboff 2022). that result told the field GLP-1 biology was not the ceiling.
-
3
wave 3 -- triple GIP/GLP-1/glucagon agonists
retatrutide layered glucagon receptor activity on top, adding an energy-expenditure and hepatic fat-mobilization arm to the appetite and incretin effects. the phase 2 obesity readout landed at ~24.2% at 48 weeks with the 12 mg arm and the curve had not plateaued (Jastreboff 2023).
how it works
retatrutide is a single 39-amino-acid peptide engineered to bind and activate three distinct receptors simultaneously. each receptor pulls on a different metabolic lever.
GLP-1 receptor
suppresses appetite via hypothalamic and brainstem GLP-1R, delays gastric emptying, and boosts glucose-dependent insulin secretion. carries most of the satiety effect and the built-in hypoglycemia safety margin (Coskun 2022).
GIP receptor
glucose-dependent insulinotropic polypeptide receptor. amplifies meal-stimulated insulin, improves lipid handling in adipose tissue, and contributes to beta-cell function. retatrutide's backbone is GIP-derived (Coskun 2022).
glucagon receptor
increases resting energy expenditure via hepatic thermogenesis and mobilizes fat out of the liver. tuned to ~20% of native glucagon activity so simultaneous GLP-1 agonism counterbalances any glycemic rise (Coskun 2022, Jastreboff 2023).
what each pathway adds in plain words
the easiest way to read the three arms is by which side of the energy equation they touch. GLP-1 and GIP both work on the "energy in" side -- they reduce how much food enters the system and how sharply glucose spikes after a meal. glucagon is the only arm that works on the "energy out" side, raising the rate at which the body burns stored fuel (Coskun 2022).
historically, glucagon agonism was avoided in diabetes drug design because pure glucagon raises blood sugar by driving hepatic glucose output. retatrutide gets around that by pairing glucagon agonism with much stronger GLP-1 agonism on the same molecule, so the glucose-lowering arms dominate and HbA1c improves rather than worsens (Rosenstock et al. 2023).
A
the headline numbers
the phase 2 obesity trial (NCT04881760), published in the new england journal of medicine in june 2023, produced the strongest randomized weight-loss signal yet reported for an investigational obesity drug.
48-week weight change by dose arm
the trial randomized 338 adults with BMI ≥ 30 (or ≥ 27 with comorbidities) to once-weekly subcutaneous retatrutide or placebo for 48 weeks. the obesity cohort excluded participants with type 2 diabetes (Jastreboff 2023). every active arm beat placebo, and the top tiers pushed into the range clinicians had historically associated with bariatric surgery rather than pharmacotherapy.
the most important caveat: the 48-week curves had not clearly plateaued at the higher doses, which is why the late-stage TRIUMPH program matters -- it will test whether the phase 2 magnitude, durability, and tolerability hold at registrational scale.
trial-design quick-reference
key terms
Definitions for the technical words that show up across this course. Tap to expand.
R
T
G
G
G
I
A
R
T
P
P
S
honest evidence ceiling
what is solid, suggestive, animal-only, or simply not studied for retatrutide as of 2026. this is the single most important slide in a course on an investigational drug.
phase 2 efficacy and core mechanism
peer-reviewed, randomized, dose-ranging human data.
- ~24.2% mean weight loss at 48 weeks at 12 mg in obesity without diabetes (Jastreboff 2023, NCT04881760).
- HbA1c reductions up to ~1.9 percentage points in the phase 2 type 2 diabetes trial (Rosenstock 2023, NCT04867785).
- in vitro triple agonism of GIP, GLP-1, and glucagon receptors verified at lilly with the published binding profile (Coskun 2022).
organ-level signals from phase 2 substudies
real human data, smaller cohorts, secondary endpoints.
- large liver-fat reductions in the phase 2a MASLD substudy (Nature Medicine 2024) -- promising but biopsy-confirmed NASH outcomes still pending.
- blood pressure and lipid improvements tracking with weight loss in the phase 2 obesity cohort.
- TRIUMPH-4 (knee osteoarthritis + obesity) topline positive in december 2025 -- full publication pending.
class-extrapolated effects
plausible from GLP-1 class data, not yet demonstrated for retatrutide specifically.
- cardiovascular event reduction -- inferred from SELECT on semaglutide (Lincoff 2023); not yet shown for retatrutide.
- kidney protection -- inferred from FLOW on semaglutide (Perkovic 2024); retatrutide is still being tested in TRIUMPH-Outcomes (NCT06383390).
- weight maintenance after discontinuation -- class data suggest substantial regain off-drug, but retatrutide-specific off-drug data are limited.
what nobody can claim yet
open questions where no published human data exist.
- long-term (5+ year) safety in any population -- the longest published exposure is the 48-week phase 2.
- head-to-head vs tirzepatide -- TRIUMPH-5 (NCT06662383) is enrolling; no published comparison exists yet.
- cardiovascular outcomes trial -- TRIUMPH-Outcomes is recruiting; MACE and kidney-event data will not read out for years.
- regulatory approval anywhere in the world -- retatrutide remains investigational as of 2026.
what's ahead
retatrutide remains in late-stage clinical development. the public TRIUMPH program is broader than the original four-study framing and now branches into multiple parallel questions.
core registrational studies in obesity without diabetes (NCT05929066), with type 2 diabetes (NCT05929079), and with established cardiovascular disease (NCT05882045).
obesity + knee osteoarthritis. lilly reported positive topline in december 2025; full publication pending.
head-to-head against tirzepatide (NCT06662383). first prospective comparison of a triple agonist with a dual agonist in obesity.
cardiovascular and kidney outcomes (NCT06383390) -- the hard endpoints that decide whether retatrutide replaces or complements existing GLP-1 therapy.
in the units ahead you move from the molecule itself (unit 2) to each of the three receptor pathways (units 3-5), then into the clinical evidence, metabolic health, liver and organ effects, safety, dosing, and the competitive obesity-drug landscape. every load-bearing claim is paired with a primary source -- this course has the highest inline-citation density of any course on the site (69 inline citations across the paid units).
Knowledge Check
Test what you've learned about retatrutide and the triple agonist concept.
Practice Exercises
Reinforce your understanding with interactive exercises.